```
      (FILE 'HOME' ENTERED AT 12:48:30 ON 02 OCT 2006)

      FILE 'REGISTRY' ENTERED AT 12:48:46 ON 02 OCT 2006
L1                STRUCTURE UPLOADED
L2              3 S L1 FAM FULL

      FILE 'CAPLUS' ENTERED AT 12:49:27 ON 02 OCT 2006
L3              8 S L2
L4              0 S L3 AND (NEUROPATHIC OR MIGRAINE OR DIABET? OR (COMPLEX(W)REGI
L5              2 S L3 AND PAIN

      FILE 'USPATFULL' ENTERED AT 12:51:44 ON 02 OCT 2006
L6              9 S L2
L7              4 S L6 AND PAIN

      FILE 'CAPLUS' ENTERED AT 13:17:33 ON 02 OCT 2006
L8              4 S L3 AND (TNF(W)(ALPHA OR A))

      FILE 'USPATFULL' ENTERED AT 13:18:30 ON 02 OCT 2006
L9              9 S L6 AND (TNF(W)(ALPHA OR A))
L10             2 S L9 NOT PY>2003
L11             1 S L9 AND PY=2003

=>
```

=> file registry
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:48:46 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6
DICTIONARY FILE UPDATES: 29 SEP 2006 HIGHEST RN 909185-74-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10693722elected.str



chain nodes :
10 11 12 13 14 15 16 18 19 20 21 22 28 29 30 31 32 33 34 35 36
37 38 39 40
ring nodes :
1 2 3 4 5 6 7 8 9 17 23 24 25 26 27
chain bonds :
1-10 2-34 3-35 4-36 7-15 8-16 9-14 10-11 10-33 11-12 11-13 16-17 16-18
16-40 18-19 19-20 19-21 19-22 23-37 24-28 25-31 26-38 27-39 28-29 29-30
31-32

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 17-23 17-27 23-24 24-25 25-26
26-27
exact/norm bonds :
1-10 5-7 6-9 7-8 7-15 8-9 8-16 9-14 10-11 11-13 19-20 19-21 24-28 25-31

exact bonds :
2-34 3-35 4-36 10-33 11-12 16-17 16-18 16-40 18-19 19-22 23-37 26-38
27-39 28-29 29-30 31-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-23 17-27 23-24 24-25 25-26 26-27

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:CLASS
19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS 29:CLASS
30:CLASS 31:CLASS
32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS 37:CLASS 38:CLASS 39:CLASS
40:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 fam full

FULL SEARCH INITIATED 12:49:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L2 3 SEA FAM FUL L1

=> d l2 scan

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[2-[(1R)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]- (9CI)
MF C22 H24 N2 O7 S

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]- (9CI)
MF C22 H24 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L2 3 ANSWERS REGISTRY COPYRIGHT 2006 ACS on STN
IN Acetamide, N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]- (9CI)
MF C22 H24 N2 O7 S

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.69	65.90

FILE 'CAPLUS' ENTERED AT 12:49:27 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Oct 2006 VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006 (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 8 L2

=> s l3 and (neuropathic or migraine or diabet? or (complex(w)regional(w)pain(w)syndrome))

```
          3962 NEUROPATHIC
          5825 MIGRAINE
        130859 DIABET?
       1284987 COMPLEX
         65910 REGIONAL
         46088 PAIN
        116757 SYNDROME
            96 COMPLEX(W)REGIONAL(W)PAIN(W)SYNDROME
L4           0 L3 AND (NEUROPATHIC OR MIGRAINE OR DIABET? OR (COMPLEX(W)REGIONA
               L(W)PAIN(W)SYNDROME))

=> s l3 and pain
         46088 PAIN
L5           2 L3 AND PAIN

=> d l5 1-2 ti abs bib

L5   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Use of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
     acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting
     TNF-α production and PDE4 activity
GI
```



I

AB The invention discloses stereomerically pure (S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione (+)-I, substantially free of its (-)-isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof. Methods of using and pharmaceutical compns. comprising (+)-I for treating and/or preventing disorders ameliorated by the reduction of levels of tumor necrosis factor α (TNF-α) or the inhibition of phosphodiesterase IV (PDE4) are also disclosed. Examples include the synthesis and resolution of (+)-I, thirteen bioassays, an aqueous solubility study, and three formulations. For instance, 3-nitrophthalic acid was hydrogenated using 10% Pd/C in EtOH to give the amine (84%), which was condensed with Ac2O to afford 3-acetamidophthalic anhydride (61%). Reaction of the phthalic anhydride with 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethylamine to give I (59%), followed by resolution with N-acetyl-L-leucine in MeOH provided (+)-I (90% recovery, 98.4% ee). The latter inhibited LPS-induced TNF-α production by human whole blood and PDE4 activity with IC50 values of 294 nM and 73.5 nM, resp. (+)-I showed >500-fold to >40,000-fold selectivity for PDE4 over PDE1, PDE2, PDE3, PDE5, and PDE6. In addition, (+)-I suppressed LPS-induced lung neutrophilia in conscious ferrets with an ED50 of 0.8 mg/kg. Thus, (+)-I and its pharmaceutical compns. are useful for treating and/or preventing cancer, depression, and a variety of allergic,

inflammatory, and autoimmune disorders (no data).

AN 2003:777583 CAPLUS <<LOGINID::20061002>>

DN 139:296870

TI Use of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting TNF-α production and PDE4 activity

IN Schafer, Peter H.; Muller, George W.; Man, Hon-Wah; Ge, Chuansheng

PA Celgene Corporation, USA

SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080049	A1	20031002	WO 2003-US8738	20030320
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479666	AA	20031002	CA 2003-2479666	20030320
	AU 2003224729	A1	20031008	AU 2003-224729	20030320
	EP 1485087	A1	20041215	EP 2003-721414	20030320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1652772	A	20050810	CN 2003-811093	20030320
	JP 2005525386	T2	20050825	JP 2003-577877	20030320
	NZ 535798	A	20060428	NZ 2003-535798	20030320
PRAI	US 2002-366515P	P	20020320		
	US 2003-438450P	P	20030107		
	WO 2003-US8738	W	20030320		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

TI Use of (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting TNF-α production and PDE4 activity

GI



I

AB The invention discloses stereomerically pure (R)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione (-)-I, substantially free of its (+)-isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof. Methods of using and pharmaceutical compns. comprising (-)-I for treating and/or preventing disorders ameliorated by the reduction of levels of tumor necrosis factor α (TNF-α) or the inhibition of phosphodiesterase IV (PDE4) are also disclosed. Examples include the synthesis and resolution of (-)-I, seven bioassays, an aqueous solubility study, and three formulations. For instance, 3-nitrophthalic acid was hydrogenated using 10% Pd/C in EtOH to give the amine (84%), which was condensed with Ac2O to afford 3-acetamidophthalic anhydride (61%). Reaction of the phthalic anhydride with 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethylamine to give I (59%), followed by resolution with N-acetyl-D-leucine in MeOH provided (-)-I (90% recovery, 98.4% ee). The latter inhibited LPS-induced TNF-α production by human whole blood and PDE4 activity with IC50 values of 371 nM and 611 nM, resp. (-)-I showed >45-fold to >39,000-fold selectivity for PDE4 over PDE1, PDE2, PDE3, PDE5, and PDE6. Thus, (-)-I and its pharmaceutical compns. are useful for treating and/or preventing cancer, depression, and a variety of allergic, inflammatory, and autoimmune disorders (no data).

AN 2003:777582 CAPLUS <<LOGINID::20061002>>

DN 139:296869

TI Use of (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting TNF-α production and PDE4 activity

IN Schafer, Peter H.; Muller, George W.; Man, Hon-Wah; Ge, Chuansheng

PA Celgene Corporation, USA

SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080048	A1	20031002	WO 2003-US8737	20030320
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003222034	A1	20031008	AU 2003-222034	20030320
PRAI	US 2002-366516P	P	20020320		
	US 2003-438448P	P	20030107		
	WO 2003-US8737	W	20030320		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.92	88.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-1.50

```
FILE 'USPATFULL' ENTERED AT 12:51:44 ON 02 OCT 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Sep 2006 (20060928/PD)
FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)
HIGHEST GRANTED PATENT NUMBER: US7114185
HIGHEST APPLICATION PUBLICATION NUMBER: US2006218687
CA INDEXING IS CURRENT THROUGH 28 Sep 2006 (20060928/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Sep 2006 (20060928/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006


=> s l2
L6            9 L2

=> s l6 and pain
         74977 PAIN
L7            4 L6 AND PAIN

=> d l7 1-4 ti

L7   ANSWER 1 OF 4  USPATFULL on STN
TI     Methods of the treatment or prevention of exercise-induced asthma using
       (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione

L7   ANSWER 2 OF 4  USPATFULL on STN
TI     Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-
       methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione

L7   ANSWER 3 OF 4  USPATFULL on STN
TI     (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione:methods of using and compositions
       thereof

L7   ANSWER 4 OF 4  USPATFULL on STN
TI     (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione: methods of using and compositions
       thereof


=> d l7 1-4 ti abs bib

L7   ANSWER 1 OF 4  USPATFULL on STN
TI     Methods of the treatment or prevention of exercise-induced asthma using
       (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione
AB     Methods of treating, managing or preventing exercise-induced asthma are
       disclosed. Specific methods encompass the administration of
       (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione alone or in combination with a second
       active agent. Pharmaceutical compositions and single unit dosage forms
       are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2006:215631  USPATFULL <<LOGINID::20061002>>
TI     Methods of the treatment or prevention of exercise-induced asthma using
       (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione
IN     Muller, George W., Bridgewater, NJ, UNITED STATES
       Schafer, Peter H., Sommerset, NJ, UNITED STATES
       Rohane, Patricia E.W., Florham Park, NJ, UNITED STATES
PA     Celgene Corporation (U.S. corporation)
```

PI US 2006183788 A1 20060817
AI US 2006-392846 A1 20060328 (11)
RLI Continuation-in-part of Ser. No. US 2005-106142, filed on 13 Apr 2005, PENDING Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, GRANTED, Pat. No. US 6962940
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 16 Drawing Page(s)
LN.CNT 1485
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 4 USPATFULL on STN
TI Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
AB Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2005:306553 USPATFULL <<LOGINID::20061002>>
TI Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Meade, NJ, UNITED STATES
PI US 2005267196 A1 20051201
AI US 2005-170308 A1 20050628 (11)
RLI Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, PENDING
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 4 USPATFULL on STN
TI (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:methods of using and compositions thereof
AB Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2005:221599 USPATFULL <<LOGINID::20061002>>
TI (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:methods of using and compositions thereof
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
PI US 2005192336 A1 20050901
AI US 2005-106142 A1 20050413 (11)
RLI Division of Ser. No. US 2003-392195, filed on 19 Mar 2003, PENDING
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US
CLMN Number of Claims: 22
ECL Exemplary Claim: 1-34
DRWN 2 Drawing Page(s)
LN.CNT 1854
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 4 USPATFULL on STN
TI (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
AB Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2003:266035 USPATFULL <<LOGINID::20061002>>
TI (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
IN Muller, George W., Bridgewater, NJ, UNITED STATES
Schafer, Peter H., Somerset, NJ, UNITED STATES
Man, Hon-Wah, Princeton, NJ, UNITED STATES
Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
PI US 2003187052 A1 20031002
US 6962940 B2 20051108
AI US 2003-392195 A1 20030319 (10)
PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> file caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      10.92      99.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)            SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -1.50

FILE 'CAPLUS' ENTERED AT 13:17:33 ON 02 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 2 Oct 2006  VOL 145 ISS 15
FILE LAST UPDATED: 1 Oct 2006  (20061001/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 and (TNF(w)(alpha or a))
         63859 TNF
       1635643 ALPHA
      20196834 A
         47923 TNF(W)(ALPHA OR A)
L8           4 L3 AND (TNF(W)(ALPHA OR A))

=> d l8 1-4 ti abs bib

L8   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Use of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
     acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting
     TNF-.alpha. production and PDE4 activity
GI
```



I

AB The invention discloses stereomerically pure (S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione (+)-I, substantially free of its (-)-isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof. Methods of using and pharmaceutical compns. comprising (+)-I for treating and/or preventing disorders ameliorated by the reduction of levels of tumor necrosis factor α (TNF-.alpha.) or the inhibition of phosphodiesterase IV (PDE4) are also disclosed. Examples include the synthesis and resolution of (+)-I, thirteen bioassays, an aqueous solubility study, and three formulations. For instance, 3-nitrophthalic acid was hydrogenated using 10% Pd/C in EtOH to give the amine (84%), which was condensed with Ac2O to afford 3-acetamidophthalic anhydride (61%). Reaction of the phthalic anhydride with 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethylamine to give I (59%), followed by resolution with N-acetyl-L-leucine in MeOH provided (+)-I (90% recovery, 98.4% ee). The latter inhibited LPS-induced TNF-.alpha. production by human whole blood and PDE4 activity with IC50 values of 294 nM and 73.5 nM, resp. (+)-I showed >500-fold to >40,000-fold selectivity for PDE4 over PDE1, PDE2, PDE3, PDE5, and PDE6. In addition, (+)-I suppressed LPS-induced lung neutrophilia in conscious ferrets with an ED50 of 0.8 mg/kg. Thus, (+)-I and its pharmaceutical compns. are useful for treating and/or preventing cancer, depression, and a variety of allergic, inflammatory, and autoimmune disorders (no data).

AN 2003:777583 CAPLUS
DN 139:296870

TI Use of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting TNF-.alpha. production and PDE4 activity

IN Schafer, Peter H.; Muller, George W.; Man, Hon-Wah; Ge, Chuansheng
PA Celgene Corporation, USA

SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003080049	A1	20031002	WO 2003-US8738	20030320
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2479666	AA	20031002	CA 2003-2479666	20030320
	AU 2003224729	A1	20031008	AU 2003-224729	20030320
	EP 1485087	A1	20041215	EP 2003-721414	20030320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1652772	A	20050810	CN 2003-811093	20030320
	JP 2005525386	T2	20050825	JP 2003-577877	20030320
	NZ 535798	A	20060428	NZ 2003-535798	20030320
PRAI	US 2002-366515P	P	20020320		
	US 2003-438450P	P	20030107		
	WO 2003-US8738	W	20030320		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting TNF-.alpha. production and PDE4 activity
GI



I

AB The invention discloses stereomerically pure (R)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione (-)-I, substantially free of its (+)-isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof. Methods of using and pharmaceutical compns. comprising (-)-I for treating and/or preventing disorders ameliorated by the reduction of levels of tumor necrosis factor α (TNF-.alpha.) or the inhibition of phosphodiesterase IV (PDE4) are also disclosed. Examples include the synthesis and resolution of (-)-I, seven bioassays, an aqueous solubility study, and three formulations. For instance, 3-nitrophthalic acid was hydrogenated using 10% Pd/C in EtOH to give the amine (84%), which was condensed with Ac2O to afford 3-acetamidophthalic anhydride (61%). Reaction of the phthalic anhydride with 1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethylamine to give I (59%), followed by resolution with N-acetyl-D-leucine in MeOH provided (-)-I (90% recovery, 98.4% ee). The latter inhibited LPS-induced TNF-.alpha. production by human whole blood and PDE4 activity with IC50 values of 371 nM and 611 nM, resp. (-)-I showed >45-fold to >39,000-fold selectivity for PDE4 over PDE1, PDE2, PDE3, PDE5, and PDE6. Thus, (-)-I and its pharmaceutical compns. are useful for treating and/or preventing cancer, depression, and a variety of allergic, inflammatory, and autoimmune disorders (no data).
AN 2003:777582 CAPLUS
DN 139:296869
TI Use of (-)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione and compositions thereof for inhibiting TNF-.alpha. production and PDE4 activity
IN Schafer, Peter H.; Muller, George W.; Man, Hon-Wah; Ge, Chuansheng
PA Celgene Corporation, USA
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003080048	A1	20031002	WO 2003-US8737	20030320

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU	2003222034	A1	20031008	AU 2003-222034	20030320
PRAI US	2002-366516P	P	20020320		
US	2003-438448P	P	20030107		
WO	2003-US8737	W	20030320		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of substituted phenethylsulfones for reducing TNF. alpha. levels
GI



I

AB The title compds. [I; the carbon atom designated "*" constitutes a center of chirality; Y = CO, CH2< CH2CO; R1-R4 = H, halo, alkyl, etc.; R5, R6 = H, alkyl, alkoxy, etc.; R7 = OH, alkyl, Ph, etc.] which reduce the levels of TNF.alpha. and inhibit PDE IV in a mammal (no data), were prepared and formulated. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline-1,3-dione.
AN 2000:78904 CAPLUS
DN 132:107873
TI Preparation of substituted phenethylsulfones for reducing TNF. alpha. levels
IN Muller, George W.; Man, Hon-wah
PA Celgene Corporation, USA
SO U.S., 13 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6020358	A	20000201	US 1998-183049	19981030
	US 6011050	A	20000104	US 1999-340617	19990629
	CA 2348993	AA	20000511	CA 1999-2348993	19991019
	WO 2000025777	A1	20000511	WO 1999-US24376	19991019
	W: AU, BR, CA, IL, IS, JP, LU, NO, NZ, PT, RU, SE, SG, ZA, AM, AZ, BY, KG, KZ, MD, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1126839	A1	20010829	EP 1999-971317	19991019

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

	BR 9915201	A	20011030	BR 1999-15201	19991019
	JP 2002528496	T2	20020903	JP 2000-579218	19991019
	AU 756308	B2	20030109	AU 2000-14472	19991019
	NZ 511253	A	20030228	NZ 1999-511253	19991019
	NO 2001002021	A	20010626	NO 2001-2021	20010424
	NO 319790	B1	20050912		
PRAI	US 1998-183049	A3	19981030		
	WO 1999-US24376	W	19991019		

OS MARPAT 132:107873
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of substituted phenethylsulfones and method of reducing TNF.alpha. levels
GI



I

AB The title compds. [I; the carbon atom designated * constitutes a center of chirality; Y = SO2, CO, CH2; R1-R4 = H, halo, alkyl, etc.; R5, R6 = H, alkyl, alkoxy, etc.; R7 = OH, alkyl, Ph, etc.], useful in reducing the levels of TNF.alpha. and inhibiting PDE IV (no data), were prepared and formulated. Typical embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-aminoisoindoline-1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-methylsulfonylethyl]isoindoline-1,3-dione (prepns. were given).
AN 2000:10631 CAPLUS
DN 132:64167
TI Preparation of substituted phenethylsulfones and method of reducing TNF.alpha. levels
IN Muller, George W.; Man, Hon-Wah
PA Celgene Corporation, USA
SO U.S., 12 pp., Division of U.S. Ser. No. 183,049.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6011050	A	20000104	US 1999-340617	19990629
	US 6020358	A	20000201	US 1998-183049	19981030
PRAI	US 1998-183049	A3	19981030		

OS MARPAT 132:64167
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file uspatfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        17.73     117.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -3.00      -4.50

FILE 'USPATFULL' ENTERED AT 13:18:30 ON 02 OCT 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 28 Sep 2006 (20060928/PD)
FILE LAST UPDATED: 28 Sep 2006 (20060928/ED)
HIGHEST GRANTED PATENT NUMBER: US7114185
HIGHEST APPLICATION PUBLICATION NUMBER: US2006218687
CA INDEXING IS CURRENT THROUGH 28 Sep 2006 (20060928/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 28 Sep 2006 (20060928/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2006


=> s l6 and (TNF(w)(alpha or a))
         29845 TNF
        577332 ALPHA
       4591510 A
         20288 TNF(W)(ALPHA OR A)
L9           9 L6 AND (TNF(W)(ALPHA OR A))

=> s l9 not py>2003
       1108505 PY>2003
L10          2 L9 NOT PY>2003

=> d l10 1-2 ti abs bib

L10  ANSWER 1 OF 2  USPATFULL on STN
TI     Substituted phenethylsulfones and method of reducing TNF.
       alpha. levels
AB     Phenethylsulfones substituted in the position α to the phenyl
       group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the
       levels of TNF.alpha. in a mammal. Typical
       embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       aminoisoindoline-1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-
       methylsulfonylethyl]isoindoline-1,3-dione.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2000:12821  USPATFULL
TI     Substituted phenethylsulfones and method of reducing TNF.
       alpha. levels
IN     Muller, George W., Bridgewater, NJ, United States
       Man, Hon-Wah, Neshanic Station, NJ, United States
PA     Celgene Corporation, Warren, NJ, United States (U.S. corporation)
PI     US 6020358              20000201
AI     US 1998-183049          19981030 (9)
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Stockton, Laura L.
LREP   Mathews, Collins, Shepherd & Gould
CLMN   Number of Claims: 19
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1277
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L10  ANSWER 2 OF 2  USPATFULL on STN
TI     Substituted phenethylsulfones and method of reducing TNF.
       alpha. levels
AB     Phenethylsulfones substituted in the position α to the phenyl
       group with a 1-oxoisoindoline or 1,3-dioxoisoindoline group reduce the
       levels of TNF.alpha. in a mammal. Typical
       embodiments are 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       aminoisoindoline-1,3-dione and 2-[1-(3-cyclopentyloxy-4-methoxyphenyl)-2-
       methylsulfonylethyl]isoindoline-1,3-dione.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2000:1893  USPATFULL
TI     Substituted phenethylsulfones and method of reducing TNF.
       alpha. levels
IN     Muller, George W., Bridgewater, NJ, United States
       Man, Hon-Wah, Neshanic Station, NJ, United States
PA     Celgene Corporation, Warren, NJ, United States (U.S. corporation)
PI     US 6011050              20000104
AI     US 1999-340617          19990629 (9)
RLI    Division of Ser. No. US 1998-183049, filed on 30 Oct 1998
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Stockton, Laura L.
LREP   Mathews, Collins, Shepherd & Gould, P.A.
CLMN   Number of Claims: 16
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> s l9 and py=2003
        401260 PY=2003
L11          1 L9 AND PY=2003

=> d l11 ti abs bib

L11  ANSWER 1 OF 1  USPATFULL on STN
TI     (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione: methods of using and compositions
       thereof
AB     Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-
       methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially
       free of its (-) isomer, and prodrugs, metabolites, polymorphs, salts,
       solvates, hydrates, and clathrates thereof are discussed. Also discussed
       are methods of using and pharmaceutical compositions comprising the (+)
       enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione are disclosed. The methods include
       methods of treating and/or preventing disorders ameliorated by the
       reduction of levels of TNF-.alpha. or the inhibition
       of PDE4.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2003:266035  USPATFULL
TI     (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-
       acetylaminoisoindoline-1,3-dione: methods of using and compositions
       thereof
IN     Muller, George W., Bridgewater, NJ, UNITED STATES
       Schafer, Peter H., Somerset, NJ, UNITED STATES
       Man, Hon-Wah, Princeton, NJ, UNITED STATES
       Ge, Chuansheng, Belle Mead, NJ, UNITED STATES
PI     US 2003187052      A1   20031002                              <--
       US 6962940         B2   20051108
AI     US 2003-392195     A1   20030319 (10)
```

PRAI US 2002-366515P 20020320 (60)
US 2003-438450P 20030107 (60)
DT Utility
FS APPLICATION
LREP PENNIE AND EDMONDS, 1155 AVENUE OF THE AMERICAS, NEW YORK, NY, 100362711
CLMN Number of Claims: 55
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 2012
CAS INDEXING IS AVAILABLE FOR THIS PATENT.